Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Osteogenic cell attachment and activation is a critical process in bone repair and regeneration, involving the binding of osteogenic precursor cells (osteoblasts, osteoprogenitors) to extracellular matrix or implanted scaffolds via specific integrin receptors, predominantly α2β1 and α5β1 integrins. Upon attachment, these receptors initiate intracellular signaling (e.g., focal adhesion kinase phosphorylation, MAPK activation) that promotes cell survival, proliferation, and eventual differentiation into bone-forming cells. Synthetic peptides (e.g., P-15) mimic collagen binding sites to enhance this process, leading to improved outcomes in bone grafting and repair[3][5]. The process is essential for physiological bone healing and is targeted in regenerative medicine but, as named, it is not a specific "therapeutic target" but rather a coordinated cellular process involving multiple molecules[3][5][8].
Promotion of cell adhesion by integrin-collagen interaction Activation of intracellular signaling cascades (including focal adhesion kinase, MAPK, and downstream osteogenic transcription factors such as Runx2 and Smads[3][1][2])
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Osteogenic cell attachment and activation (Null).